Gerinnungsfaktoren und ischämische Herzkrankheit: Eine Zusammenfassung der Zusammenhänge und ihrer Bedeutung

T. W. Meade

doi:10.1055/s-0038-1660300

Hämostaseologie, Table of Contents

Hamostaseologie 1991; 11(04): 167-171
DOI: 10.1055/s-0038-1660300

Originalarbeiten

Schattauer GmbH

Gerinnungsfaktoren und ischämische Herzkrankheit: Eine Zusammenfassung der Zusammenhänge und ihrer Bedeutung

Authors

T. W. Meade

¹MRC Epidemiology and Medical Care Unit, Northwick Park Hospital, Middlesex, England

Abstract

Zusammenfassung

Thrombosen tragen zu nahezu allen Episoden des Myokardinfarktes und des koronaren Todes bei. Hohe Fibrinogenspiegel, hohe Faktor-Vll-Aktivitäten und auch andere Komponenten des Gerinnungssystems beeinflussen die Thrombusbildung. Hohe Fibrinogenspiegel erhöhen die Viskosität, steigern die Plättchenaggregation, die Menge des gebildeten Fibrins und die Entwicklung der Atherome, hohe Faktor-Vll-Aktivitäten die Thrombinbildung. Die wichtigsten Umwelteinflüsse sind das Rauchen für den Fibrinogenspiegel und das Nahrungsfett für die Faktor-VlI-Aktivität. Es mehren sich Hinweise auf eine Senkung der Fibrinogenspiegel durch intensives Training. Bei Erstellung des Risikoprofils für die ischämische Herzkrankheit sollte der Fibrinogenspiegel vermehrt Berücksichtigung finden. Zur pharmakologischen Primärprevention könnten niedere Dosen von ASS und eine schwache orale Antikoagulation, einzeln oder in Kombination, geeignet sein, doch müssen noch die Ergebnisse laufender, randomisierter, kontrollierter Studien abgewartet werden.

Full Text

References

LITERATUR
1 Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of Factor X activation in humans. Blood 1989; 74: 2007-15.
2 Bauer KA, Kass NL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990; 76: 731-6.
3 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50.
4 Chandler AB, Chapman I, Erhardt LR. et al. Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am J Cardiol 1974; 34: 823-33.
5 Dantzig JM, van Becker AE. Sudden cardiac death and acute pathology of coronary arteries. Eur Heart J 1986; 07: 987-91.
6 Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137-40.
7 Davies MJ. Thrombosis in acute myocardial infarction and sudden death. In: Thrombosis and Platelets in Myocardial Ischemia. Mehta JL, Conti CR, Brest AN. (eds). Philadelphia: F A Divis Company; 1987: 151-9.
8 DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-901.
9 El Fawal MA, Berg GA, Wheatley DJ, Harland WA. Sudden coronary death in Glasgow: Nature and frequency of acute coronary lesions. Br Heart J 1987; 57: 329-35.
10 Frink RJ, Rooney Jr PA, Trowbridge JO, Rose J. Coronary thrombosis and platelet/ fibrin microemboli in death associated with acute myocardial infarction. Br Heart J 1988; 59: 196-200.
11 Green FR, Kelleher CK, Wilkes HC, Temple A, Meade TW, Humphries SE. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arteriosclerosis and Thrombosis 1991; 11: 540-6.
12 Hamsten A, de Faire U, Wallius G. et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; II: 3-9.
13 Hamsten A, Iselius L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987; II: 988-90.
14 Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80: 749-56.
15 Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; I: 1452-5.
16 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; II: 349-60.
17 Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA 1987; 258: 1183-6.
18 Meade TW, Chakrabarti R, Haines AP, Howarth DJ, North WRS, Stirling Y. Haemostatic, lipid and blood-pressure profiles of women on oral contraceptives containing 50 g or 30 (ig oestrogen. Lancet 1977; II: 948-51.
19 Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: Sex differences and effects of the menopause. Br J Haematol 1990; 74: 77-81.
20 Meade TW. Epidemiology of atheroma, thrombosis and ischaemic heart disease. In: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (eds.) Churchill Livingstone. 1987: 697-720.
21 Meade TW. The epidemiology of haemostatic and other variables in coronary artery disease. In: Thrombosis and Haemostasis 1987. Verstraete M, Vermylen J, Lijnen R, Arnout J. (eds). Leuven University Press; 1987: 37-60.
22 Meade TW. Low-dose warfarin and lowdose aspirin in the primary prevention of ischemic heart disease. Am J Cardiol 1990; 65: 7c-11c.
23 Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987; II: 986-8.
24 Meade TW, North WRS, Chakrabarti R, Stirling Y, Haines AP, Thompson SG. Haemostatic function and cardiovascular death: Early results of a prospective study. Lancet 1980; I: 1050-4.
25 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; II: 533-7.
26 Meade TW, North WRS. Population-based distributions of haemostatic variables. Br Med Bull 1977; 33: 283-8.
27 Meade TW, Wilkes HC, Stirling Y, Brennan PJ, Kelleher C, Browne W. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: Design and pilot study. Eur Heart J 1988; 09: 836-43.
28 Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Antithrombin III and arterial disease: An unexpected relationship. Lancet. 1991 (in press).
29 Miller GJ, Martin JC, Webster J, Wilkes H, Miller NE, Wilkinson WH, Meade TW. Association between dietary fat intake and plasma factor VII coagulant activity a predictor of cardiovascular mortality. Atherosclerosis 1986; 60: 269-77.
30 Miller GJ, Cruickshank JK, Ellis LJ, Thompson RL, Wilkes HC, Stirling Y, Mitropoulos KA, Allison JV, Fox TE, Walker AO. Fat consumption and factor VII coagulant activity in middle-aged men. An association between a dietary and thrombogenic coronary risk factor. Atherosclerosis 1989; 78: 19-24.
31 Peto R, Gray R, Collins R. et al. Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313-6.
32 Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129-35.
33 Poller L. Thrombosis and factor VII activity. J Clin Path 1957; 10: 348-50.
34 RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30.
35 Rosendaal FR, Varekamp I, Smit C. et al. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989; 71: 71-6.
36 Stone MC, Thorp JM. Plasma fibrinogen a major coronary risk factor. Journal of the Royal College of General Practitioners 1985; 35: 565-9.
37 Thomas AE, Green FR, Kelleher CH. et al. Variation in the promoter region of the B fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991; 65: 487-90.
38 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
39 Wilkes HC, Kelleher C, Meade TW. Smoking and plasma fibrinogen (letter). Lancet 1988; I: 307-8.
40 Yarnell JWG, Baker IA, Sweetnam PM. et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991; 83: 836-44.